Description
BOLD-100 is a first-in-class, clinical-stage investigational therapy being developed for the treatment of patients with cancer and viral infections, including COVID-19. BOLD-100 has previously been shown to have antiviral activity against S…
Amendment chain · 4 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $289,032 at start, $1,464,715 after amendment #5 (+$1,175,683).
- #02020-11-25$289,032
- #32021-03-23$499,215+$210,183
- #42021-06-07$1,464,715+$965,500
- #52021-09-27$1,464,715
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2020-11-25(start date) | $289,032 | — | BOLD-100 is a first-in-class, clinical-stage investigational therapy being developed for the treatment of pati… |
| #3 amendment | 2021-03-23 | $499,215 | +$210,183 | BOLD-100 is a first-in-class, clinical-stage investigational therapy being developed for the treatment of pati… |
| #4 amendment | 2021-06-07 | $1,464,715 | +$965,500 | BOLD-100 is a first-in-class, clinical-stage investigational therapy being developed for the treatment of pati… |
| #5 amendment | 2021-09-27 | $1,464,715 | +$0 | BOLD-100 is a first-in-class, clinical-stage investigational therapy being developed for the treatment of pati… |
Related records · 11
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 748003712)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2025-2026-Q4-1038281 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program | $75,000 | FY2026 |
| 172-2024-2025-Q4-1028202 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Youth Employment Program | $30,000 | FY2025 |
| 172-2023-2024-Q3-1013318 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $24,580 | FY2024 |
| 172-2022-2023-Q3-997677 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $740,700 | FY2023 |
| 172-2022-2023-Q4-1001187 | National Research Council Canada | Conseil national de recherches Canada · CanExport Innovation | $18,097 | FY2023 |
| 172-2022-2023-Q3-993126 | National Research Council Canada | Conseil national de recherches Canada · CanExport Innovation | $13,658 | FY2023 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2020-2021-Q3-961802 · retrieved 2026-11-12.